IN8BIO, INC. (INAB) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Company: IN8BIO, INC.
Reporting Period: Quarter ended September 30, 2024 (Q3 2024)
Business Overview: IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell product candidates for solid and liquid tumors. The lead candidate, INB-100, is in an investigator-sponsored Phase 1 trial for acute myeloid leukemia (AML). The company operates as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(7,086) | $(7,169) | $(24,277) | $(22,409) |
| Net Loss Per Share (Basic/Diluted) | $(0.15) | $(0.23) | $(0.53) | $(0.79) |
| Cash and Restricted Cash | $4,260 | $13,108 | $4,260 (End of Period) | $13,108 (End of Period) |
| Accumulated Deficit | $(115,496) | $(83,621) | $(115,496) | $(83,621) |
| Operating Cash Flow (9 Months) | $(20,121) | $(18,490) | $(20,121) | $(18,490) |
Material Changes vs. Prior Period
- Workforce Reduction: In September 2024, the company reduced its workforce by approximately 49% across all functions. This resulted in one-time severance and related charges of $1.1 million in Q3 2024, including $0.8 million in accelerated stock-based compensation.
- Pipeline Prioritization: The company suspended further development of INB-400 (glioblastoma) to focus resources on INB-100 (AML) and preclinical programs. Consequently, direct R&D expenses for INB-400 are expected to cease, though costs were incurred prior to suspension.
- Compensation Reduction: Executive management and the Board agreed to an 11% reduction in cash compensation effective September 1, 2024.
- Cash Position: Cash and restricted cash decreased by approximately $8.8 million from the prior year-end ($21.5 million to $4.3 million) due to operating losses and capital expenditures, partially offset by financing activities.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: The filing states there is substantial doubt about the company's ability to continue as a going concern for 12 months from the issuance date. Management expects existing cash ($4.0 million) plus net proceeds from a subsequent private placement ($11.6 million) to fund operations through December 2025.
- Subsequent Financing: In October 2024, the company completed a private placement raising $11.6 million net proceeds. This included the issuance of common stock, pre-funded warrants, and Series C warrants.
- Warrant Amendments: In connection with the private placement, Series A warrants were amended to reduce the exercise price from $1.25 to $0.45 and extend the expiration date to October 4, 2025.
- Regulatory Risks: The company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement ($1.00 per share) and has until February 3, 2025, to regain compliance.
- Outlook: The company plans to present updated INB-100 data at the American Society of Hematology Annual Meeting in December 2024. It is seeking strategic partnerships for its suspended INB-400 program and preclinical assets.
Investor Verification Checklist
- Cash Runway: Verify the actual closing of the October 2024 private placement and confirm the total cash balance available to fund operations through the projected December 2025 date.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the February 3, 2025 deadline to avoid delisting.
- INB-100 Data: Review the data presentation at the December 2024 ASH meeting to assess the clinical progress and potential for regulatory advancement.
- Partnership Status: Track progress on securing a strategic partner for the INB-400 program, as the company has suspended enrollment and is seeking collaboration to fund further development.
- Warrant Exercise: Assess the likelihood of Series A, B, and C warrant exercises, which could provide up to ~$31.6 million in gross proceeds but are not guaranteed.